Adenosine A2A receptor blockers reversed chronic cannabinoid-induced memory deficits in rats
Chronic treatment with an adenosine A2A receptor antagonist (istradefylline) reversed memory deficits caused by chronic cannabinoid exposure in rats, without changing receptor levels in the brain.
Quick Facts
What This Study Found
Chronic istradefylline (3 mg/kg/28 days) reversed memory deficits (Novel Object Recognition Test) caused by chronic WIN 55,212-2 (1 mg/kg/28 days). In hippocampal slices, the A2A antagonist partially rescued cannabinoid-impaired long-term potentiation. Neither chronic treatment affected A2A or CB1 receptor binding in hippocampus or prefrontal cortex.
Key Numbers
Istradefylline 3 mg/kg/day for 28 days reversed memory deficits. WIN 55,212-2 300 nM impaired hippocampal LTP. SCH 58261 100 nM partially rescued LTP. No changes in A2A or CB1 receptor binding after chronic treatment.
How They Did This
Chronic 28-day treatment in rats with behavioral memory testing (NORT), electrophysiological hippocampal recordings (LTP), and receptor binding assays for A2A and CB1 receptors in hippocampus and PFC.
Why This Research Matters
Patients on long-term cannabinoid therapies (e.g., for epilepsy, pain, spasticity) may experience cognitive side effects. If A2A antagonists can reverse these without affecting cannabinoid therapeutic efficacy, they could be valuable co-treatments.
The Bigger Picture
Istradefylline is already FDA-approved for Parkinson's disease. Repurposing it to mitigate cannabinoid cognitive side effects would be faster than developing a new drug, and this study provides the rationale.
What This Study Doesn't Tell Us
Rat model using a synthetic cannabinoid (WIN 55,212-2), not THC or CBD. LTP rescue was partial, not complete. Behavioral assessment limited to object recognition. 28-day treatment may not predict longer-term outcomes.
Questions This Raises
- ?Would istradefylline prevent THC or CBD cognitive side effects in humans?
- ?Does A2A antagonism interfere with cannabinoid therapeutic effects (seizure control, pain relief)?
Trust & Context
- Key Stat:
- Memory deficits reversed
- Evidence Grade:
- Preliminary: rat study with a synthetic cannabinoid, though using an already-approved drug.
- Study Age:
- Published in 2019.
- Original Title:
- Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism.
- Published In:
- Neuropharmacology, 155, 10-21 (2019)
- Authors:
- Mouro, Francisco M, Köfalvi, Attila, André, Luís A, Baqi, Younis, Müller, Christa E, Ribeiro, Joaquim A, Sebastião, Ana M
- Database ID:
- RTHC-02197
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can memory problems from cannabinoids be reversed?
In rats, chronic treatment with an adenosine A2A receptor blocker (already approved for Parkinson's) completely reversed memory deficits caused by chronic cannabinoid exposure.
How does this work?
A2A receptors interact with CB1 receptors in the hippocampus. Blocking A2A receptors partially restored the synaptic plasticity that cannabinoids impaired, rescuing memory function.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-02197APA
Mouro, Francisco M; Köfalvi, Attila; André, Luís A; Baqi, Younis; Müller, Christa E; Ribeiro, Joaquim A; Sebastião, Ana M. (2019). Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism.. Neuropharmacology, 155, 10-21. https://doi.org/10.1016/j.neuropharm.2019.05.003
MLA
Mouro, Francisco M, et al. "Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism.." Neuropharmacology, 2019. https://doi.org/10.1016/j.neuropharm.2019.05.003
RethinkTHC
RethinkTHC Research Database. "Memory deficits induced by chronic cannabinoid exposure are ..." RTHC-02197. Retrieved from https://rethinkthc.com/research/mouro-2019-memory-deficits-induced-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.